Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of your Favored Travel Movement - 2Most loved VR Game for Wellness: Which Keeps You Dynamic?
- 3Well known SUVs With Low Energy Utilization In 2024 vote
- 4Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- 5When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- Lula’s former human rights minister formally accused of sexual misconduct
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- EU calls on Western Balkans to step up reforms for membership
- Why most Jewish Israelis back the death penalty for terrorists
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Asia's Noteworthy Destinations: A Voyager's Aide
